The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo
Mohamed H. Sayegh(American University of Beirut), Alison M. Paterson(Brigham and Women's Hospital), Arlene H. Sharpe(Brigham and Women's Hospital), Anil Chandraker(Brigham and Women's Hospital), Xiaozhi Zhao(Brigham and Women's Hospital), Bruce R. Blazar(University of Minnesota Medical Center), Scott J. Rodig(Brigham and Women's Hospital), Miyuki Azuma(Tokyo Medical and Dental University), Vijay K. Vanguri(University of Massachusetts Chan Medical School), Hideo Yagita∥(Juntendo University), Gordon J. Freeman(Dana-Farber Cancer Institute), Leonardo V. Riella(Massachusetts General Hospital), Susanne Chock(Brigham and Women's Hospital), Tao Liu(PowerChina (China)), Toshihiko Watanabe(Brigham and Women's Hospital), Xueli Yuan(Brigham and Women's Hospital)
Cited by 133
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
|Nature Medicine|2007|2.2k
Identifying ChIP-seq enrichment using MACS
|Nature Protocols|2012|2.1k